Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype. - Wikidata - awgldk - TriplyDB

Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype.

Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype.

http://www.wikidata.org/entity/Q37589614

about

Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy.Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.

P2860

Q39213123-DE1F4D07-5E11-43D0-9E76-589EC26F8FC9 Q39342422-5EAF1B95-FEE6-4A3B-9871-8FB1BDDCC0F4

P2860

Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype.

http://www.wikidata.org/entity/Q37589614

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Non-Ambulant Duchenne Patients ...... kipping have Severe Phenotype.

@en

Non-Ambulant Duchenne Patients ...... kipping have Severe Phenotype.

@nl

type

label

Non-Ambulant Duchenne Patients ...... kipping have Severe Phenotype.

@en

Non-Ambulant Duchenne Patients ...... kipping have Severe Phenotype.

@nl

prefLabel

Non-Ambulant Duchenne Patients ...... kipping have Severe Phenotype.

@en

Non-Ambulant Duchenne Patients ...... kipping have Severe Phenotype.

@nl

P1433

Q37589614-8EA70ED4-44AC-471F-B7A3-23A1C858DFB6

P1476

Q37589614-E90E64AD-5EBE-4D5B-89BA-704FE44640DD

P2093

Q37589614-01AA5F48-2D7A-4671-814F-5CCD6901FB00

Q37589614-1D5789E8-980D-453C-BD0B-9DD3E93665F0

Q37589614-1DD2A5DD-DB31-4547-A088-A4E8D276327A

Q37589614-1E5040CA-53A5-4E1F-91FD-136C784CC07D

Q37589614-24C42205-C603-446C-811C-98B8C0D555AF

Q37589614-4CE9AF7D-55FC-4750-931C-613ABE301CE4

Q37589614-5B6A848C-576C-4059-AAA0-2B37D625C4D8

Q37589614-5D0E0306-99C6-4ED6-97E9-C47E921554A6

Q37589614-6B5BE30C-27AA-4848-885E-0DD64154D10C

Q37589614-72CAB550-81BF-4864-AE98-E9672449948A

P2860

Q37589614-003B8B57-A79C-4DE3-8E18-AFD84881ED05

Q37589614-257C7C48-6782-4773-AADA-245E895DC619

Q37589614-2BE1516D-CB0A-4298-AE82-FE1B6D9F40FE

Q37589614-325048AE-AD0F-41A6-A9BB-BAE4841D4AD0

Q37589614-4FD59B51-A500-47FA-A0B4-6AB08488298A

Q37589614-5CCA4D21-DE72-4473-A422-A1A8636E496A

Q37589614-5ED424E7-AD3F-4423-AFBF-FC4CCB075A05

Q37589614-6C449C70-C8B3-4C3E-A711-2502C4020AB1

Q37589614-71A838A0-19D2-4555-9E3F-F9D226FCCCB6

Q37589614-80F7B8CA-CFB7-4ADF-B199-83EEF6858AEC

P304

Q37589614-E25AF185-E443-4396-AD3C-2B589166C0E1

P31

Q37589614-DD180675-D362-4111-9BDA-4A589E2635B0

P356

Q37589614-DECCE0FD-625D-44A0-BDD2-B57B0F8FBC14

P433

Q37589614-71EEFFBA-9F8F-4B07-BD2D-430A381A050A

P478

Q37589614-181A7704-4423-42FE-A002-C3A383CD1323

P50

Q37589614-07990290-032B-47F3-B01F-5040B2E07B74

Q37589614-7BC73DA6-2722-4555-AC02-B97D738B58C8

Q37589614-DDDA0C8F-81DB-427E-AB59-415D341EA3B2

P577

Q37589614-B5198409-693E-42B6-BB50-DA76A14109BB

P698

Q37589614-A0EAB3AE-6334-4C0E-92FF-5AB72B37A187

P932

Q37589614-3D62A6CC-03EE-49EE-B9F7-D85D1A0312CD

P356

P1433

Journal of neuromuscular diseases

P1476

Non-Ambulant Duchenne Patients ...... Skipping have Severe Phenotype

@en

P2093

Amélie Moraux

http://www.w3.org/2001/XMLSchema#string

Andrea Klein

http://www.w3.org/2001/XMLSchema#string

Andreea M Seferian

http://www.w3.org/2001/XMLSchema#string

Anne-Gaëlle Le Moing

http://www.w3.org/2001/XMLSchema#string

Caroline Le Guiner

http://www.w3.org/2001/XMLSchema#string

Catherine Vanhulle

http://www.w3.org/2001/XMLSchema#string

Claude Cances

http://www.w3.org/2001/XMLSchema#string

France Leturcq

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Cuisset

http://www.w3.org/2001/XMLSchema#string

Karima Zehrouni

http://www.w3.org/2001/XMLSchema#string

P2860

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy

Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.

The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing an

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle

Systemic administration of PRO051 in Duchenne's muscular dystrophy.

Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene.

Dystrophin and mutations: one gene, several proteins, multiple phenotypes.

Stature is an essential predictor of muscle strength in children.

Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.

P304

269-279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JND-150100

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Yves Hogrel

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27858743

http://www.w3.org/2001/XMLSchema#string

P932

5240539

http://www.w3.org/2001/XMLSchema#string